Pricing, Tariffs, Manufacturing, Politics: What’s Really in the MFN Deals

The first Most-Favored-Nation (MFN) deal documents are now public, and they cover a lot more than price. Tariffs, manufacturing commitments, and other policy terms are woven in as well. In FirstWord PHARMA’s latest “Spotlight On”, Moira Ringo, VP, Market Access Strategy, shares her perspectives on these deals and what to look for beyond the headline.

Key takeaways:

• Price is only one piece of a much bigger deal. These agreements don’t just set drug prices, they also bundle in commitments on US import tariffs, domestic manufacturing investment, and other policy trade-offs.
• Is this a genuine shift, or an easy concession? It’s worth asking whether some companies are giving up things that cost them little or that they’d likely have done regardless making the deals look bigger than their real financial impact.
• A press announcement isn’t proof of impact. The real test of whether a deal actually changes a company’s business is what shows up later in its financial disclosures, not the headlines on announcement day. That gap can be significant.
• The fine print can tell a different story. Exclusions and redacted terms matter enormously, as details buried in these documents can undercut the headline claims.
• These deals are political as well as commercial. With US midterm elections approaching, provisions tied to domestic manufacturing jobs and supply chain resilience are as much about politics as they are about healthcare policy, so it’s worth reading with that lens in mind.
• US and international markets are becoming harder to separate. These deals tie US drug prices directly to prices abroad, and that linkage looks set to continue. Open questions remain for ex-US markets: how it affects launch timing for new drugs, and whether some products get withdrawn from certain markets altogether.

The article is available now for FirstWord PHARMA+ subscribers:

• The MFN receipts are in but experts still can’t see the bottom line